Questions Answered in This Report:
- What are the treatment drivers and goals for moderate to severe ulcerative colitis?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe ulcerative colitis?
- What are the prevailing areas of unmet need and opportunity in moderate to severe ulcerative colitis?
- What trade-offs across different clinical attributes and price are acceptable to and European gastroenterologists for a hypothetical new moderate to severe ulcerative colitis drug?
Current therapies, or combinations thereof, used to treat moderate to severe ulcerative colitis are moderately effective in managing patient symptoms. However, efficacy limitations and/or safety risks with long-term use still exist. Therefore, a substantial level of unmet need remains in the treatment of ulcerative colitis, and addressing this need could result in substantial commercial opportunity.
Unmet Need provides quantitative insight into and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need associated with the treatment of moderate to severe ulcerative colitis. We analyze the commercial opportunities and how emerging therapies can capitalize on these opportunities.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 and 31 European gastroenterologists fielded in December 2016
Key companies: AbbVie, Biogen, Celgene, Celltrion, Janssen, Merck, Pfizer, Roche, Shire, Takeda
Key drugs: Azathioprine, Entyvio, etrolizumab, Flixabi, Humira, Inflectra, Lialda/Mezavant/Mesavant XL , ozanimod, Remicade, Remsima, Simponi, Xeljanz